Detalhe da pesquisa
1.
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial.
Crit Care Med;
51(1): 103-116, 2023 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36519984
2.
Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis.
J Allergy Clin Immunol;
150(6): 1517-1524, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36041655
3.
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.
J Allergy Clin Immunol;
148(3): 790-798, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33872652
4.
Development of AITC-induced dermal blood flow as a translational in vivo biomarker of TRPA1 activity in human and rodent skin.
Br J Clin Pharmacol;
87(1): 129-139, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32415670
5.
Myeloperoxidase Attenuates Pathogen Clearance during Plasmodium yoelii Nonlethal Infection.
Infect Immun;
85(1)2017 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27795354
6.
A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
Hum Vaccin Immunother;
11(10): 2370-5, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26114800
7.
Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Hum Vaccin Immunother;
10(2): 441-8, 2014.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24240428